Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.37 |
| ▸ | SCNN1A | P37088 | 10/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965503 | 0.93 | SCNN1A (0.41) | ADRB2CHRM3ADRB3SCNN1A | |
| SCHEMBL2054454 | 0.83 | SCNN1A (0.42) | ADRB2ADRB3SCNN1A | |
| SCHEMBL965884 | 0.83 | ADRB3 (0.49) | ADRB2CHRM3ADRB3SCNN1A | |
| SCHEMBL2056238 | 0.83 | ADRB3 (0.49) | ADRB2CHRM3ADRB3SCNN1A | |
| Acetic Acid SCHEMBL966119 | 0.82 | SCNN1A (0.40) | ADRB2ADRB3SCNN1A | |
| Acetic Acid SCHEMBL966116 | 0.82 | SCNN1A (0.40) | ADRB2ADRB3SCNN1A | |
| SCHEMBL963895 | 0.81 | SCNN1A (0.43) | ADRB2ADRB3SCNN1A | |
| SCHEMBL963899 | 0.81 | SCNN1A (0.43) | ADRB2ADRB3SCNN1A | |
| SCHEMBL2056265 | 0.81 | ADRB2 (0.48) | ADRB2CHRM3ADRB3SCNN1A | |
| SCHEMBL2054471 | 0.81 | ADRB2 (0.48) | ADRB2CHRM3ADRB3SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163758-B2 | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity | PARION SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | CACNA1C, CACNA1B, CACNA1G | ADRB2 40/4885CHRM3 274/4885ADRB3 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.